Posts

Showing posts with the label Drug Discovery Informatics Market Share

Drug Discovery Informatics Market Size Poised To Reach USD 5.63 Billion By 2028

  San Francisco, 24 March 2021:   The Report  Drug Discovery Informatics Market  Size, Share & Trends Analysis Report By Mode (In-house, Outsourced), By Workflow (Discovery, Development), By Services (Sequence Analysis Platforms, Docking), And Segment Forecasts, 2021 - 2028 The global drug discovery informatics market size is expected to reach USD 5.63 billion by 2028 registering a CAGR of 11.3% over the forecast period, according to a new report by Grand View Research, Inc. Use of drug discovery software for gaining market intelligence owing to several advantages, such as rapid drug design & synthesis, efficient tracking of disease evolution, and data integrity management, has increased significantly among the researchers in the recent years, driving the industry growth. The growing demand for novel molecules is driving the adoption of informatics solutions targeted towards speeding up the entire drug discovery process by identifying rational drug molecules via the target macr

Drug Discovery Informatics Market Exhibiting At A CAGR Of 12.6% For The Forecast Period From 2018 - 2025 : Grand View Research Inc.

San Francisco, 9 July 2019:   The Report   Drug Discovery Informatics Market  Size, Share & Trends Analysis Report By Workflow (Discovery, Development), By Mode (In-house, Outsourced), By Services, By Region, Vendor Landscape, And Segment Forecasts, 2018 – 2025 The global drug discovery informatics market size is expected to reach USD 2.07 billion by 2025, according to a new report by Grand View Research, Inc., progressing at a CAGR of 12.6% during the forecast period. Drug therapy is evolving in response to health care needs of the population. The most recent trend is to develop drugs for treatment of chronic diseases, especially those affecting the older population. Cardiovascular Diseases (CVDs), stroke, and cancer are the most prevalent health issues and also the most common conditions causing death. Moreover, treatment expenses and costs pertaining to these diseases are very high, which triggers the demand for effective novel molecules. In the U.S. alone, revenue generate